ZA202006190B - Rimegepant for cgrp related disorders - Google Patents
Rimegepant for cgrp related disordersInfo
- Publication number
- ZA202006190B ZA202006190B ZA2020/06190A ZA202006190A ZA202006190B ZA 202006190 B ZA202006190 B ZA 202006190B ZA 2020/06190 A ZA2020/06190 A ZA 2020/06190A ZA 202006190 A ZA202006190 A ZA 202006190A ZA 202006190 B ZA202006190 B ZA 202006190B
- Authority
- ZA
- South Africa
- Prior art keywords
- rimegepant
- related disorders
- cgrp related
- disclosed
- pharmaceutical compositions
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
- A61K9/0056—Mouth soluble or dispersible forms; Suckable, eatable, chewable coherent forms; Forms rapidly disintegrating in the mouth; Lozenges; Lollipops; Bite capsules; Baked products; Baits or other oral forms for animals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
- A61K9/006—Oral mucosa, e.g. mucoadhesive forms, sublingual droplets; Buccal patches or films; Buccal sprays
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2013—Organic compounds, e.g. phospholipids, fats
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2013—Organic compounds, e.g. phospholipids, fats
- A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/2063—Proteins, e.g. gelatin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Pain & Pain Management (AREA)
- Nutrition Science (AREA)
- Physiology (AREA)
- Zoology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (6)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862647794P | 2018-03-25 | 2018-03-25 | |
| US201862664761P | 2018-04-30 | 2018-04-30 | |
| US201862774285P | 2018-12-02 | 2018-12-02 | |
| US201862777180P | 2018-12-09 | 2018-12-09 | |
| US201862777625P | 2018-12-10 | 2018-12-10 | |
| PCT/US2019/023940 WO2019191008A1 (en) | 2018-03-25 | 2019-03-25 | Rimegepant for cgrp related disorders |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ZA202006190B true ZA202006190B (en) | 2025-07-30 |
Family
ID=68060723
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ZA2020/06190A ZA202006190B (en) | 2018-03-25 | 2020-10-06 | Rimegepant for cgrp related disorders |
| ZA2022/04929A ZA202204929B (en) | 2018-03-25 | 2022-05-05 | Rimegepant for cgrp related disorders |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ZA2022/04929A ZA202204929B (en) | 2018-03-25 | 2022-05-05 | Rimegepant for cgrp related disorders |
Country Status (20)
| Country | Link |
|---|---|
| US (3) | US20210000814A1 (https=) |
| EP (3) | EP3773572A4 (https=) |
| JP (2) | JP2021519288A (https=) |
| KR (1) | KR20200135465A (https=) |
| CN (1) | CN112153969A (https=) |
| AU (1) | AU2019242604B2 (https=) |
| BR (1) | BR112020019396A2 (https=) |
| CA (1) | CA3094693A1 (https=) |
| DK (1) | DK4088720T3 (https=) |
| ES (1) | ES3047659T3 (https=) |
| FI (1) | FI4088720T3 (https=) |
| IL (1) | IL277272B1 (https=) |
| MX (1) | MX2020009856A (https=) |
| PH (1) | PH12020551425A1 (https=) |
| PL (1) | PL4088720T3 (https=) |
| PT (1) | PT4088720T (https=) |
| SG (1) | SG11202009199YA (https=) |
| SI (1) | SI4088720T1 (https=) |
| WO (1) | WO2019191008A1 (https=) |
| ZA (2) | ZA202006190B (https=) |
Families Citing this family (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SI4088720T1 (sl) * | 2018-03-25 | 2026-01-30 | Pfizer Ireland Pharmaceuticals Unlimited Company | Rimegepant za motnje, povezane s cgrp |
| JP2022517433A (ja) * | 2019-01-20 | 2022-03-08 | バイオヘイブン・ファーマシューティカル・ホールディング・カンパニー・リミテッド | 突出性の片頭痛を処置するためのｃｇｒｐアンタゴニスト |
| CA3164445A1 (en) * | 2019-12-17 | 2021-06-24 | Biohaven Pharmaceutical Holding Company Ltd. | Intranasal pharmaceutical compositions of cgrp inhibitors |
| JP2023515535A (ja) * | 2020-02-27 | 2023-04-13 | バイオヘイブン・ファーマシューティカル・ホールディング・カンパニー・リミテッド | リメゲパントの経口急速分散剤形 |
| WO2021194918A1 (en) * | 2020-03-23 | 2021-09-30 | Biohaven Pharmaceutical Holding Company Ltd. | Methods of treating pulmonary injury with cgrp inhibitors |
| MX2022012001A (es) * | 2020-03-29 | 2022-10-21 | Biohaven Pharmaceutical Ireland Dac | Tratamiento preventivo de la migra?a. |
| WO2022103638A1 (en) | 2020-11-16 | 2022-05-19 | Orcosa Inc. | Cannabinoids in the treatment of autism spectrum disorder |
| US11672761B2 (en) | 2020-11-16 | 2023-06-13 | Orcosa Inc. | Rapidly infusing platform and compositions for therapeutic treatment in humans |
| IL302948A (en) * | 2020-11-19 | 2023-07-01 | Pfizer Ireland Pharmaceuticals | Compositions for improved delivery of cgrp inhibitors |
| CN116456981A (zh) * | 2020-11-19 | 2023-07-18 | 辉瑞爱尔兰制药公司 | 用于改善的grp抑制剂递送的组合物 |
| US20230285380A1 (en) * | 2021-05-25 | 2023-09-14 | Biohaven Pharmaceutical Ireland Dac | Dual treatment of migraine |
| CN115850266A (zh) * | 2021-09-26 | 2023-03-28 | 奥锐特药业(天津)有限公司 | 瑞美吉泮新晶型及其制备方法 |
| WO2023055758A1 (en) * | 2021-09-29 | 2023-04-06 | Pfizer Ireland Pharmaceuticals | Preventative treatment of migraine |
| CN114010608A (zh) * | 2021-11-23 | 2022-02-08 | 莱默(北京)药业科技有限公司 | 一种瑞美吉泮冻干口崩片及制备方法 |
| CN115154469A (zh) * | 2022-07-22 | 2022-10-11 | 中国科学院广州生物医药与健康研究院 | 瑞美吉泮或其药学上可接受的盐在制备预防或治疗肥胖的药物中的应用 |
| WO2024062504A1 (en) * | 2022-09-22 | 2024-03-28 | Quisitive Therapeutics | Pharmaceutical composition comprising ubrogepant and administration thereof |
| WO2024211881A1 (en) * | 2023-04-06 | 2024-10-10 | Navinta, Llc | Rimegepant suspension |
| WO2024220974A1 (en) * | 2023-04-21 | 2024-10-24 | Navinta, Llc | Rimegepant fast-dissolving films for oral administration |
| CN117414352A (zh) * | 2023-11-22 | 2024-01-19 | 湖北广济医药科技有限公司 | 一种瑞美吉泮口溶膜剂及其制备方法 |
| WO2025193980A2 (en) * | 2024-03-13 | 2025-09-18 | CNS Biosciences, Inc. | Method of treating neuropathic pain using an anti-cgrp inhibitor |
Family Cites Families (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB1548022A (en) | 1976-10-06 | 1979-07-04 | Wyeth John & Brother Ltd | Pharmaceutial dosage forms |
| GB9817793D0 (en) | 1998-08-14 | 1998-10-14 | Scherer Corp R P | The formation of indicia in the base of a blister pack for transference to a body cast therein |
| US7704583B2 (en) | 1998-08-14 | 2010-04-27 | R.P.Scherer Technologies, Inc. | Embossed blister pack |
| GB9908014D0 (en) | 1999-04-08 | 1999-06-02 | Scherer Corp R P | Pharmaceutical compositions |
| WO2007016087A2 (en) * | 2005-07-29 | 2007-02-08 | Merck & Co., Inc. | Heterocyclic benzodiazepine cgrp receptor antagonists |
| US8715715B2 (en) * | 2008-11-03 | 2014-05-06 | Nal Pharmaceuticals Ltd. | Dosage form for insertion into the mouth |
| US8314117B2 (en) | 2009-10-14 | 2012-11-20 | Bristol-Myers Squibb Company | CGRP receptor antagonists |
| US8669368B2 (en) | 2010-10-12 | 2014-03-11 | Bristol-Myers Squibb Company | Process for the preparation of cycloheptapyridine CGRP receptor antagonists |
| ES2746031T3 (es) * | 2012-02-27 | 2020-03-04 | Bristol Myers Squibb Co | Sal de N-(5S,6S,9R)-5-amino-6-(2,3-difluorofenil)-6,7,8,9-tetrahidro-5H-ciclohepta[B]piridin-9-IL-4-(2-oxo-2,3-dihidro-1H-imidazo[4,5-B]piridin-1-il)piperidina-1-carboxilato |
| US20130225336A1 (en) * | 2012-02-28 | 2013-08-29 | Edward R. Harvey | Method and apparatus for teaching the throwing of a curveball without injury |
| EP2815749A1 (en) * | 2013-06-20 | 2014-12-24 | IP Gesellschaft für Management mbH | Solid form of 4-amino-2-(2,6-dioxopiperidine-3-yl)isoindoline-1,3-dione having specified X-ray diffraction pattern |
| JP6491669B2 (ja) * | 2014-02-05 | 2019-03-27 | メルク・シャープ・アンド・ドーム・コーポレーションＭｅｒｃｋ Ｓｈａｒｐ ＆ Ｄｏｈｍｅ Ｃｏｒｐ． | Ｃｇｒｐ活性化合物の錠剤製剤 |
| CA2921336A1 (en) * | 2015-06-30 | 2016-12-30 | Gilead Sciences, Inc. | Pharmaceutical formulations |
| GB201519196D0 (en) * | 2015-10-30 | 2015-12-16 | Heptares Therapeutics Ltd | CGRP Receptor Antagonists |
| SI4088720T1 (sl) * | 2018-03-25 | 2026-01-30 | Pfizer Ireland Pharmaceuticals Unlimited Company | Rimegepant za motnje, povezane s cgrp |
| JP2022517433A (ja) * | 2019-01-20 | 2022-03-08 | バイオヘイブン・ファーマシューティカル・ホールディング・カンパニー・リミテッド | 突出性の片頭痛を処置するためのｃｇｒｐアンタゴニスト |
-
2019
- 2019-03-25 SI SI201930982T patent/SI4088720T1/sl unknown
- 2019-03-25 JP JP2020551496A patent/JP2021519288A/ja not_active Withdrawn
- 2019-03-25 WO PCT/US2019/023940 patent/WO2019191008A1/en not_active Ceased
- 2019-03-25 PT PT221827561T patent/PT4088720T/pt unknown
- 2019-03-25 CA CA3094693A patent/CA3094693A1/en active Pending
- 2019-03-25 IL IL277272A patent/IL277272B1/en unknown
- 2019-03-25 MX MX2020009856A patent/MX2020009856A/es unknown
- 2019-03-25 PL PL22182756.1T patent/PL4088720T3/pl unknown
- 2019-03-25 SG SG11202009199YA patent/SG11202009199YA/en unknown
- 2019-03-25 EP EP19776794.0A patent/EP3773572A4/en not_active Withdrawn
- 2019-03-25 EP EP22182756.1A patent/EP4088720B1/en active Active
- 2019-03-25 KR KR1020207030358A patent/KR20200135465A/ko not_active Ceased
- 2019-03-25 CN CN201980034240.4A patent/CN112153969A/zh active Pending
- 2019-03-25 AU AU2019242604A patent/AU2019242604B2/en active Active
- 2019-03-25 FI FIEP22182756.1T patent/FI4088720T3/fi active
- 2019-03-25 EP EP25192368.6A patent/EP4631944A3/en active Pending
- 2019-03-25 DK DK22182756.1T patent/DK4088720T3/da active
- 2019-03-25 US US16/767,134 patent/US20210000814A1/en not_active Abandoned
- 2019-03-25 ES ES22182756T patent/ES3047659T3/es active Active
- 2019-03-25 BR BR112020019396-8A patent/BR112020019396A2/pt unknown
-
2020
- 2020-05-27 US US16/884,196 patent/US11083724B2/en active Active
- 2020-09-10 PH PH12020551425A patent/PH12020551425A1/en unknown
- 2020-10-06 ZA ZA2020/06190A patent/ZA202006190B/en unknown
-
2021
- 2021-08-08 US US17/396,717 patent/US20220168295A1/en not_active Abandoned
-
2022
- 2022-05-05 ZA ZA2022/04929A patent/ZA202204929B/en unknown
-
2023
- 2023-07-18 JP JP2023116385A patent/JP2023134690A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| WO2019191008A1 (en) | 2019-10-03 |
| US20220168295A1 (en) | 2022-06-02 |
| BR112020019396A2 (pt) | 2021-01-05 |
| EP4631944A3 (en) | 2025-12-24 |
| EP4088720B1 (en) | 2025-09-03 |
| PT4088720T (pt) | 2025-10-15 |
| SG11202009199YA (en) | 2020-10-29 |
| DK4088720T3 (da) | 2025-09-29 |
| EP4631944A2 (en) | 2025-10-15 |
| FI4088720T3 (fi) | 2025-11-14 |
| ES3047659T3 (en) | 2025-12-04 |
| IL277272A (en) | 2020-10-29 |
| AU2019242604A1 (en) | 2020-10-22 |
| JP2023134690A (ja) | 2023-09-27 |
| IL277272B1 (en) | 2024-09-01 |
| EP3773572A1 (en) | 2021-02-17 |
| EP4088720A1 (en) | 2022-11-16 |
| ZA202204929B (en) | 2024-10-30 |
| MX2020009856A (es) | 2020-10-08 |
| PL4088720T3 (pl) | 2025-12-15 |
| SI4088720T1 (sl) | 2026-01-30 |
| US20200383969A1 (en) | 2020-12-10 |
| AU2019242604B2 (en) | 2025-01-02 |
| US11083724B2 (en) | 2021-08-10 |
| CA3094693A1 (en) | 2019-10-03 |
| US20210000814A1 (en) | 2021-01-07 |
| PH12020551425A1 (en) | 2021-12-13 |
| KR20200135465A (ko) | 2020-12-02 |
| EP3773572A4 (en) | 2022-01-05 |
| JP2021519288A (ja) | 2021-08-10 |
| CN112153969A (zh) | 2020-12-29 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ZA202204929B (en) | Rimegepant for cgrp related disorders | |
| MX2024010140A (es) | Nuevos metodos. | |
| SA518392101B1 (ar) | ROR-Gamma مشتقات البنزيميدازول في صورة مُعدلات لـ | |
| PH12020551578A1 (en) | Modulators of methyl modifying enzymes, compositions and uses thereof | |
| MX393855B (es) | Terapia de combinación que comprende un inhibidor de raf y trametinib | |
| PH12020551043A1 (en) | Compounds, compositions, and methods for treatment of diseases involving acidic or hypoxic diseased tissues | |
| EA201992607A1 (ru) | Твердые формы берберина урсодезоксихолата, их композиции и способы | |
| MX385332B (es) | Moduladores de ror-gamma. | |
| PH12021550671A1 (en) | Prodrugs of cgrp antagonists | |
| PH12021550443A1 (en) | Pyridazinones and methods of use thereof | |
| MX2016010034A (es) | Inhibidores de dihidropirrolopiridina de receptor huerfano relacionado-gamma. | |
| PH12019501896A1 (en) | Therapeutic dendrimers | |
| ZA201607489B (en) | Combination comprising a glucocorticoid and edo-s101 | |
| TW201613578A (en) | Pharmaceutical combinations | |
| MX2021010297A (es) | Inhibidores de calicreina plasmatica humana. | |
| MX2022012001A (es) | Tratamiento preventivo de la migra?a. | |
| PH12021550143A1 (en) | Pyridopyrimidines as histamine h4-receptor inhibitors | |
| EA201892311A1 (ru) | Производные 2-анилинопиримидина в качестве терапевтических агентов для лечения рака мозга | |
| ZA202211253B (en) | Compositions comprising 15-hepe for treating or preventing hematologic disorders, and/or related diseases | |
| MY189372A (en) | Indole derivatives | |
| SA520420147B1 (ar) | ("tcd") مثبطات إفراز بروتين أساسها تراي أزا سيكلو دوديكان سلفوناميد | |
| EA202092278A1 (ru) | Римегепант для связанных с cgrp расстройств | |
| EA202090416A1 (ru) | Способы лечения симптомов гастропареза с использованием велусетрага | |
| EA201891739A1 (ru) | ПРИМЕНЕНИЕ СТИМУЛЯТОРОВ sGC ДЛЯ ЛЕЧЕНИЯ НЕАЛКОГОЛЬНОГО СТЕАТОГЕПАТИТА (NASH) | |
| MX2019014773A (es) | Inhibidores de ccl2. |